TW200605916A - Crystalline composition containing escitalopram - Google Patents

Crystalline composition containing escitalopram

Info

Publication number
TW200605916A
TW200605916A TW094104639A TW94104639A TW200605916A TW 200605916 A TW200605916 A TW 200605916A TW 094104639 A TW094104639 A TW 094104639A TW 94104639 A TW94104639 A TW 94104639A TW 200605916 A TW200605916 A TW 200605916A
Authority
TW
Taiwan
Prior art keywords
escitalopram
crystalline particles
composition containing
escitalopram oxalate
crystalline composition
Prior art date
Application number
TW094104639A
Other languages
Chinese (zh)
Inventor
Kim Bojstrup Jensen
Rikke Eva Humble
Ken Liljegren
Troels Volsgaard Christensen
Original Assignee
Lundbeck & Co As H
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lundbeck & Co As H filed Critical Lundbeck & Co As H
Publication of TW200605916A publication Critical patent/TW200605916A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4816—Wall or shell material
    • A61K9/4825—Proteins, e.g. gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

The present invention discloses crystalline particles of escitalopram oxalate which either have a broad particle size distribution or comprise at least 0.01 % (w/w) of Z-4-(4-dimethylamino-1-(4-fluorophenyl)-but-1-enyl)-3-hydroxymethyl-benzonitrile, said particles being suitable for use in direct compression. Furthermore, the invention discloses a novel pharmaceutical unit dosage form containing such crystalline particles of escitalopram oxalate as well as methods for manufacture of such crystalline particles of escitalopram oxalate. Finally, the invention provides a method for reduction of the amount of hydroxyl containing impurities in a solution of citalopram or escitalopram.
TW094104639A 2004-03-05 2005-02-17 Crystalline composition containing escitalopram TW200605916A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DKPA200400382 2004-03-05

Publications (1)

Publication Number Publication Date
TW200605916A true TW200605916A (en) 2006-02-16

Family

ID=36607154

Family Applications (1)

Application Number Title Priority Date Filing Date
TW094104639A TW200605916A (en) 2004-03-05 2005-02-17 Crystalline composition containing escitalopram

Country Status (9)

Country Link
KR (1) KR20060126587A (en)
CN (3) CN101492435A (en)
AR (1) AR047749A1 (en)
IL (1) IL177504A0 (en)
MY (1) MY142756A (en)
PE (1) PE20051162A1 (en)
SG (1) SG159504A1 (en)
TW (1) TW200605916A (en)
ZA (1) ZA200607382B (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114763343A (en) * 2021-01-14 2022-07-19 浙江华海药业股份有限公司 Method for purifying citalopram or S-citalopram
CN113663356B (en) * 2021-08-23 2022-09-23 广西埃索凯新材料科技有限公司 Crystallization impurity removal monitoring system applied to manganese sulfate production

Also Published As

Publication number Publication date
PE20051162A1 (en) 2006-01-16
MY142756A (en) 2010-12-31
ZA200607382B (en) 2008-05-28
CN101492435A (en) 2009-07-29
SG159504A1 (en) 2010-03-30
CN1925844A (en) 2007-03-07
KR20060126587A (en) 2006-12-07
AR047749A1 (en) 2006-02-15
CN101492436A (en) 2009-07-29
IL177504A0 (en) 2006-12-10

Similar Documents

Publication Publication Date Title
MXPA05010682A (en) Novel compounds.
BR0206164A (en) Escitalopram oxalate crystalline particles, method for the production of escitalopram oxalate crystalline particles, and solid unit dosage form
MY142029A (en) Phenoxyacetic acid derivatives
UA86595C2 (en) Gamma-crystalline form of the chlorohydrate of ivabradine, process for its preparation and pharmaceutical compositions containing it
WO2004014322A3 (en) Immunomodulatory compositions, methods of making, and methods of use thereof
UA100228C2 (en) Pharmaceutical composition containing a tetrahydrofolic acid
GEP20074030B (en) Controlled synthesis of ziprasidone and compositions thereof
WO2008064351A3 (en) (r)-n-stereoisomers of 7,8-saturated-4,5-epoxy-morphinanium analogs
ME01394B (en) Crystalline form gamma-d of the chlorohydrate of ivabradine, process for its preparation and pharmaceutical compositions containing it
MXPA04004956A (en) Piperidine-based mch antagonists for treatment of obesity and cns disorders.
AU2002326072A1 (en) Fluoro and sulphonylamino containing 3,6-disubstituted azabicyclo (3.1.0) hexane derivatives as muscarinic receptor antagonists
WO2010131922A3 (en) Amide compound, preparation method thereof and pharmaceutical composition comprising same
UA96308C2 (en) Glucagon receptor antagonist compounds, composition comprising such compounds and use thereof
WO2011065800A3 (en) Pyrimidine derivative, method for preparing same and pharmaceutical composition containing same
MXPA04003858A (en) Mch antagonists for the treatment of obesity.
UA103179C2 (en) Pharmaceutical composition comprising ezetimibe
WO2006000224A3 (en) Compositions comprising strontium and vitamin d and uses thereof
TW200510367A (en) Novel lapachone compounds, their preparation, and the use thereof
WO2008102321A3 (en) Oral polyphosphate compositions
UA95088C2 (en) Composition comprising at least one anticancer drug and at least one polymer and reducing chemotherapy-induced alopecia, process for the preparation thereof
IL160171A0 (en) Depsipeptide derivatives, processes for the preparation thereof and pharmaceutical compositions containing the same
HK1126194A1 (en) Novel benzamidine derivatives, process for the preparation thereof and pharmaceutical composition comprising the same
WO2007087026A3 (en) Solid-state form of amg 706 and pharmaceutical compositions thereof
MY137846A (en) Processes for the preparation of oral dosage formulations of modafinil
EA200601641A1 (en) CRYSTAL COMPOSITION CONTAINING ESCYTAL PREMAX OXALATE